|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||228.189 g·mol−1|
|3D model (JSmol)|
Triazavirin (TZV) is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.
It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus, and Forest-Spring Encephalitis virus, and is also being investigated for potential application against Lassa fever and Ebola virus disease. In February 2020, testing of triazavirin was started against SARS-CoV-2.
- Rusinov VL, Sapozhnikova IM, Ulomskii EN, Medvedeva NR, Egorov VV, Kiselev OI, et al. (2015). "Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins". Chemistry of Heterocyclic Compounds. 51 (3): 275–280. doi:10.1007/s10593-015-1695-4.
- Loginova SI, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, et al. (2007). "[Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 52 (11–12): 18–20. PMID 19275052.
- Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, Ulomsky E, et al. (May 2010). "Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication". Antimicrobial Agents and Chemotherapy. 54 (5): 2017–22. doi:10.1128/AAC.01186-09. PMC 2863629. PMID 20194696.
- Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, et al. (2012). "[A new antiviral drug Triazavirin: results of phase II clinical trial]". Voprosy Virusologii (in Russian). 57 (6): 9–12. PMID 23477247.
- Loginova SI, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON (2014). "[Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 59 (1–2): 3–5. PMID 25051708.
- Loginova SY, Borisevich SV, Rusinov VL, Ulomsky EN, Charushin VN, Chupakhin ON, Sorokin PV. Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice (Russian). Antibiot Khimioter. 2015;60(7-8):11-3. PMID 26863736
- "Target: Ebola". Pravda. 2014-12-22. Retrieved 18 January 2015.
- "Yekaterinburg pharmacies to sell domestic antiviral drug". Retrieved 18 January 2015.
- Cox, Simon (2014-10-17). "Ebola crisis: Vaccine 'too late' for outbreak. BBC News, 17 October 2014". BBC News.
- Kukil Bora. Russia Will Begin Testing Triazavirin, Used For Lassa Fever, And Other Drugs On Ebola: Health Ministry. International Business Times, 12 November 2014
- Darya Kezina. New antiviral drug from Urals will help fight Ebola and other viruses. Russia Beyond the Headlines, 12 November 2014
- Jamshaid U. China Testing Russia's Triazavirin As Coronavirus Treatment - Russian Health Ministry. Urdupoint, 4 Feb 2020
- "China tests Russian anti-viral drug which might treat coronavirus as Moscow warns of possible 'mass outbreak'". Retrieved 11 February 2020.
- "China Tests Russian Antiviral Drug Which Might Treat Coronavirus As Moscow Warns Of Possible 'Mass Outbreak'". 2020-02-05. Retrieved 11 February 2020.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|